BiondVax

Corporate brand

BiondVax is an Israeli biopharmaceutical company developing immunotherapeutic products for infectious and autoimmune diseases.

Last updated August 24, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on the research, development, and manufacture of immunotherapeutic products. Its work has primarily addressed infectious diseases and autoimmune conditions, placing the company within the biotechnology and specialty-pharmaceutical sectors rather than the general consumer vaccine market. The company’s research history includes development of a broadly targeted influenza vaccine candidate and a later shift toward nanosized antibody, or NanoAb, therapies. BiondVax’s influenza program was evaluated through a substantial clinical-development effort. According to the company’s reference material, it conducted eight clinical trials, including a Phase 3 study involving approximately 12,400 participants across seven countries. The program was intended to address the limitations of conventional seasonal influenza vaccines by seeking broader protection across influenza strains. In a Phase IIb trial reported in 2017, the candidate was described as demonstrating broad strain coverage. The available reference material does not establish that the candidate received regulatory approval or became a marketed vaccine, so it is best characterized as a clinical-stage development program rather than a commercial product. The company also owns and operates a biologics manufacturing facility containing laboratories, production facilities, and offices. This infrastructure supports BiondVax’s position as a biotechnology company with both research and manufacturing capabilities. No specific manufacturing scale, regulatory certifications, commercial production volumes, or current product revenues are identified in the supplied sources. In December 2021, BiondVax entered into definitive agreements with the Max Planck Society, the parent organization of the Max Planck Institute for Multidisciplinary Sciences, and the University Medical Center Göttingen in Germany. The collaboration is directed toward the development and commercialization of NanoAb therapies for COVID-19 and other diseases. The referenced research areas include COVID-19, asthma, and psoriasis. NanoAbs are described as nanosized antibody therapies intended to act against disease-related biological targets. The partnership connects BiondVax’s development and manufacturing capabilities with research institutions in Germany and broadens the company’s focus beyond influenza. BiondVax’s positioning is therefore based on translational biotechnology: it combines clinical development, biologics manufacturing, and collaborations with academic and medical institutions. Its potential offerings are therapeutic and preventive biologic products rather than conventional branded medicines already established in mass retail channels. The supplied references do not provide a current commercial product list, regulatory approvals, executive roster, financial information, or confirmed corporate ownership structure. Those omissions limit the extent to which the company’s present commercial scale can be assessed.

History

BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company whose activities have centered on immunotherapeutic research, clinical development, and biologics manufacturing. Its stated therapeutic interests include infectious diseases and autoimmune diseases. The company’s development history is notable for an influenza vaccine program followed by a strategic emphasis on nanosized antibody therapies. The influenza program sought to provide broader protection than conventional seasonal influenza vaccines, which are generally designed around selected circulating strains. BiondVax advanced its candidate through a series of clinical studies. The company is reported to have conducted eight clinical trials in total, including a large Phase 3 study conducted across seven countries and involving approximately 12,400 participants. This made the influenza program one of the most substantial elements of the company’s clinical-development history. In 2017, the candidate was reported to have shown broad strain coverage in a Phase IIb trial. The supplied reference does not identify a final regulatory approval, commercial launch, or sustained market presence for the vaccine, and therefore the program should be described as a clinical-stage effort rather than as an established marketed product. BiondVax also developed internal infrastructure to support biologics work. It owns and operates a facility that houses laboratories, production facilities, and offices. This is significant to the company’s business model because it indicates an effort to maintain capabilities extending beyond early discovery. However, the available material does not specify the facility’s production capacity, regulatory status, manufacturing partners, or the extent of commercial output. A major strategic development occurred in December 2021, when BiondVax signed definitive agreements with the Max Planck Society and the University Medical Center Göttingen. The Max Planck Society is the parent organization of the Max Planck Institute for Multidisciplinary Sciences, and the collaboration links BiondVax with German academic and medical research institutions. The partners agreed to work on the development and commercialization of NanoAb therapies. These nanosized antibody products were associated with potential applications in COVID-19, asthma, and psoriasis. The NanoAb collaboration broadened BiondVax’s scope from vaccine development into targeted antibody therapeutics. It also illustrates the company’s reliance on partnerships as a route to combine academic discovery, clinical translation, and industrial development. The COVID-19 focus emerged during a period of intense global interest in new antibody and vaccine approaches, while the asthma and psoriasis programs extended the potential application of the platform into chronic inflammatory and autoimmune conditions. BiondVax’s historical profile is consequently that of a specialized Israeli biotechnology company rather than a large diversified pharmaceutical group. Its principal assets described in the supplied sources are its clinical-development experience, biologics facility, immunotherapy focus, and collaborations with research organizations. The available references do not provide a confirmed founder, headquarters address, executive list, ownership structure, revenue figures, regulatory approvals, or details of marketed products. These areas require additional authoritative sourcing before they can be added to the company record.

2021
NanoAb strategic collaboration established
[1]BiondVaxen.wikipedia.org
In December 2021, BiondVax signed definitive agreements with the Max Planck Society and University Medical Center Göttingen to develop and commercialize NanoAb therapies.
2017
Influenza candidate showed broad strain coverage in Phase IIb
[1]BiondVaxen.wikipedia.org
BiondVax’s influenza vaccine candidate was reported in a Phase IIb trial to have broad strain coverage, supporting the program’s aim of addressing multiple influenza strains.

Products and positioning

Israeli biotechnology company focused on clinically developed and manufacturable immunotherapies, with programs spanning broad-coverage influenza vaccines and nanosized antibody treatments for infectious and autoimmune diseases.

Vaccine candidate
Influenza vaccine candidate
BiondVax’s influenza program was designed to provide broad protection across influenza strains. It progressed through multiple clinical studies, including a Phase IIb trial and a large Phase 3 trial conducted across seven countries with approximately 12,400 participants. The candidate was reported in 2017 to have broad strain coverage. The supplied sources do not establish regulatory approval or commercial launch.
Antibody therapeutics
NanoAb therapies
NanoAbs are nanosized antibody therapies being developed by BiondVax in collaboration with the Max Planck Society and University Medical Center Göttingen. The referenced application areas include COVID-19, asthma, and psoriasis. The program represents an expansion from influenza vaccine development into targeted biologic therapies for infectious, respiratory, and inflammatory or autoimmune conditions.

Brand decisions

2021
Expanded into NanoAb therapeutics through German research collaborationStrategy
Background
Following its influenza vaccine development work, BiondVax pursued nanosized antibody therapies for infectious and autoimmune-related conditions.
Action taken
In December 2021, the company signed definitive agreements with the Max Planck Society and University Medical Center Göttingen to develop and commercialize NanoAb products.
Aftermath
The collaboration broadened BiondVax’s stated pipeline to include potential therapies for COVID-19, asthma, and psoriasis. The supplied sources do not report subsequent approvals, launches, or financial outcomes.
Source

Recent events

2021
BiondVax entered NanoAb development collaboration with Max Planck Society and University Medical Center Göttingen[1]BiondVaxen.wikipedia.org
Product launch
In December 2021, BiondVax signed definitive agreements with the Max Planck Society and the University Medical Center Göttingen to develop and commercialize nanosized antibody therapies, initially including programs for COVID-19 and research areas such as asthma and psoriasis.
2017
BiondVax influenza vaccine candidate reported broad strain coverage in Phase IIb trial[1]BiondVaxen.wikipedia.org
Product generation · Other
BiondVax’s influenza vaccine candidate was reported to have demonstrated broad strain coverage in a Phase IIb clinical trial. The available material does not state that the candidate subsequently received marketing authorization.

Sources7 sources

Cite this profile: Cite the canonical profile. /brand-wiki/biondvax · Editorial policy · How profiles are compiled